Evidence map›Paper›PMID 36538113›Full record

ArticleJournal of ophthalmic inflammation and infection2022

Ocular symptoms in COVID-19 infection: a survey study.

Matthew McHarg, Yujuan Wang, Mehmet Yakin, Alex Zeleny, Sonny Caplash, H Nida Sen, Shilpa Kodati

Open access · goldAbstract read
In one paragraph

Article in Journal of ophthalmic inflammation and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Neuro-Ophthalmology at a glance.Taiwan journal of ophthalmology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Matthew McHargNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA.
Yujuan WangNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA.
Mehmet YakinNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA.
Alex ZelenyNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA.
Sonny CaplashDepartment of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
H Nida SenNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA.
Shilpa KodatiNational Eye Institute, National Institutes of Health, 10 Centre Drive, 10/10N248, Bethesda, MD, USA. Shilpa.Kodati@nih.gov.
National Institutes of Health · USMinistry of Health · TRNational Eye Institute · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) systemic symptoms and sequelae have been studied extensively, but less is known about the characterization, duration, and long-term sequelae of ocular symptoms associated with COVID-19 infection. The purpose of this study was to analyze the frequency, spectrum, and duration of ocular symptoms in participants with COVID-19 infection treated in inpatient and outpatient settings.

methodsA retrospective electronic survey was distributed to NIH employees and the public who reported testing positive for SARS-CoV-2. The anonymous survey collected information on demographics, past ocular history, systemic COVID-19 symptoms, and ocular symptoms.

resultsA total of 229 (21.9% male and 78.1% female, mean age 42.5 ± 13.9) survey responses were included. Ocular symptoms were reported by 165 participants with a mean of 2.31 ± 2.42 symptoms. The most commonly reported ocular symptoms were light sensitivity (31.0%), itchy eyes (24.9%), tearing (24.9%), eye redness (24.5%), and eye pain (24.5%). Participants with ocular symptoms had a higher number of systemic symptoms compared to participants without ocular symptoms (mean 9.17 ± 4.19 vs 6.22 ± 3.63; OR: 1.21; 95% CI: 1.11 - 1.32; p < 0.001). Ocular symptoms were more common in those who reported a past ocular history compared to those who did not (81.8% vs 67.1%; OR: 2.17; 95% CI: 1.08 - 4.37; p = 0.03). Additionally, the onset of ocular symptoms occurred most frequently at the same time as systemic symptoms (47.5%), and 21.8% reported symptoms lasting ≥ 14 days.

conclusionsOcular surface-related symptoms are the most frequent ocular manifestations, and systemic disease severity is associated with the presence of ocular symptoms. Additionally, our results show that ocular symptoms can persist post-COVID-19 infection. Further work is needed to better understand ocular symptoms in COVID-19 and long-term sequelae.

Indexed as

COVID-19InfectionInflammationOcular surfaceSurvey study

Identifiers

PMID36538113
PMCPMC9765365
OpenAlexW4312093668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.